Fierce Biotech January 7, 2025
Gabrielle Masson, Darren Incorvaia

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry.

We’re maintaining the criteria we used for last year’s tracker, which means including financing rounds north of $50 million. Of course, we’ll still profile innovative new companies and larger rounds in-depth, while we focus more coverage on clinical trial results, M&A and special reports.

January

Jan. 6—Orbis Medicines
Series: A
Amount: €90 million (About $93.4 million)
Investors: NEA (New Enterprise Associates), Eli Lilly, Cormorant, the Export and Investment Fund of Denmark, and founding...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
The Download: what’s next for AI, and stem-cell therapies
You, Me, and Our Microbiome
Trendspotting: Predictions for Bio-IT World in 2025
The Future of Cancer Drug Development: Advancements, Challenges, and the Transformative Role of AI
J&J says its lung cancer drug combination keeps people alive longer

Share This Article